Related Experiment Video
Updated: Dec 21, 2025
11:59
Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
Published on: September 6, 2017
7.7K
Promising Response to Thalidomide in Symptomatic β-Thalassemia
1Department of Medicine, College of Medicine, Hawler Medical university, Erbil, Iraq.
Summary
Low-dose thalidomide shows promise for treating thalassemia patients who cannot tolerate standard therapies. This hemoglobin F (HbF) inducer significantly improved outcomes in both transfusion-dependent and non-transfusion-dependent thalassemia groups.
Area of Science:
- Hematology
- Pharmacology
- Genetics
Background:
- Thalassemia is a group of inherited blood disorders.
- Conventional treatments like transfusions and chelation are not suitable for all patients.
- Thalidomide, an HbF inducer, has shown potential in limited studies.
Purpose of the Study:
- To evaluate the efficacy and safety of low-dose thalidomide in patients with symptomatic beta-thalassemia syndrome.
- To assess response rates in transfusion-dependent thalassemia (TDT) and non-transfusion-dependent thalassemia (NTDT) patients.
Main Methods:
- A cohort of 37 TDT and NTDT patients received low-dose thalidomide (2-10 mg/kg).
- Patients were monitored for a minimum of 8 months.
- Response was defined as a 25% reduction in transfusion needs for TDT and a 1 g/dL hemoglobin increase for NTDT.
Main Results:
- 75.7% of patients responded to thalidomide within a mean of 1.7 months.
- NTDT patients showed a significant hemoglobin increase (7.83 to 9.96 g/dL).
- TDT patients experienced a significant drop in annual transfusions (27 to 7.79 units).
Conclusions:
- Low-dose thalidomide is effective in a majority of TDT and NTDT patients.
- The observed benefits were sustained with minimal side effects.
- Thalidomide may offer a valuable therapeutic option for specific thalassemia patient subsets.
Related Concept Videos
01:22Bone Marrow Sampling and Transplants
728
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
728
01:07Teratogenicity
3.8K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
3.8K
01:22iPS Cell Differentiation
3.0K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
3.0K
00:59Gene Therapy
27.2K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.2K